The third phase of the Cardiac Rehabilitation Program (CRP) is a lifelong, maintenance phase beginning 3 to 6 months after the cardiac event. Individualized surveillance and monitoring schedules are established. The exercise prescription guidelines are practically identical to those of the other phases of the CRP with personalized monitoring. Currently, with the emergence of the COVID-19 pandemic, telerehabilitation and telemonitoring are of great value in this phase. The benefits of phase 3 have been demonstrated with prolonged survival by 1.82 years, at a cost of $ 1773 per year of life saved.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23736/S0031-0808.21.04315-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Network analysis of socioeconomic disparities and public transport in COVID-19 spread: a case study in northeast Brazil.
J Infect Dev Ctries
December 2024
Graduate Program in Health Sciences, Federal University of Sergipe, SE, Brazil.
Introduction: The coronavirus disease 2019 (COVID-19) pandemic has significantly impacted public transportation systems worldwide. In this study, we evaluated the rate of COVID-19 positivity and its associated factors among users of public transportation in socioeconomically disadvantaged regions of Brazil during the pre-vaccination phase of the pandemic.
Methodology: This ecological study, conducted in Aracaju city in Northeast Brazil, is a component of the TestAju Program.
Prevalence of SARS-CoV-2 infections and socio-occupational profile of delivery riders during the COVID-19 pandemic.
J Infect Dev Ctries
December 2024
Federal University of São João Del Rei, Dona Lindu Campus, Sebastião Gonçalves Coelho Street, 400, Chanadour, 35501-296 Divinópolis, MG, Brazil.
Introduction: We assessed the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and associated socio-occupational factors among delivery riders from a Brazilian city at two time points during the pandemic.
Methodology: Surveys for antibody and viral RNA testing were conducted from November 2020 to January 2021, and from March to May 2021 in a group of 117 delivery riders. A questionnaire on socio-occupational characteristics and coronavirus disease 2019 (COVID-19) preventive measures was completed.
Impact of Periodontal Treatment on Early Rheumatoid Arthritis and the Role of Porphyromonas gingivalis Antibody Titers.
Med Sci Monit
January 2025
Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
BACKGROUND Periodontal disease and rheumatoid arthritis (RA) are closely related, and periodontal therapy can potentially improve RA activity. However, it is not clear in which RA patient populations are more effective periodontal therapy for RA treatment. This study aimed to evaluate the effects of treatment for periodontal disease in 30 patients with rheumatoid arthritis and the titers of antibodies to Porphyromonas gingivalis (P.
View Article and Find Full Text PDFSpecialized pediatric palliative care in Italy: where are we going? The Palliped 2022-2023 study.
Ital J Pediatr
January 2025
Polistudium SRL, Milan, Italy.
Background: The PalliPed project is a nationwide, observational, cross-sectional study designed with the aim of providing a constantly updated national database for the census and monitoring of specialized pediatric palliative care (PPC) activities in Italy. This paper presents the results of the first monitoring phase of the PalliPed project, which was developed through the PalliPed 2022-2023 study, to update current knowledge on the provision of specialized PPC services in Italy.
Methods: Italian specialized PPC centers/facilities were invited to participate and asked to complete a self-reporting, ad-hoc, online survey regarding their clinical activity in 2022-2023, in the revision of the data initially collected in the first PalliPed study of 2021.
Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.
Virol J
January 2025
Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, Guangdong, 518118, China.
Background: SHEN26 (ATV014) is an oral RNA-dependent RNA polymerase (RdRp) inhibitor with potential anti-SARS-CoV-2 activity. Safety, tolerability, and pharmacokinetic characteristics were verified in a Phase I study. This phase II study aimed to verify the efficacy and safety of SHEN26 in COVID-19 patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!